Power of the press: journal changes study after critical news story In an uncommon move, a journal offers actually eliminated in and transformed a previously-stated bottom line of the previously-published paper.This comes after a Reuters Wellness story that raised questions about the scholarly study. The edits come times after a Reuters Health story about serious shortcomings in the report. Dr.Peer review has imperfections.Conflict appealing disclosure guidelines are variable and also have openings in them.A radical thought – but one We harbor frequently: Probably we simply spend an excessive amount of news time, space and attention on journal content articles.But kudos to Reuters for pulling a number of the addresses from this one.Particularly, the researchers viewed prescriptions for warfarin between 2004 and 2012 and any kind of fresh cases of prostate, lung, breast and cancer of the colon between 2006 and 2012. Among 1.25 million people, 93 nearly,000 were acquiring warfarin. Warfarin’s anti-cancer impact was especially strong among individuals taking it for atrial fibrillation, Lorens said. The analysis had some limitations. Because Lorens’ group did not gather information on various other medicines or risk elements, fresh cancers might have been recurrences of earlier ones. Also, warfarin prescriptions could be a marker for other factors that will help prevent malignancy, they added. The report was published online Nov.